{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:28:37Z","timestamp":1793672917937,"version":"4.5.1"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Korea Ministry of Science and ICT","doi-asserted-by":"publisher","award":["2022R1A5A8033794"],"award-info":[{"award-number":["2022R1A5A8033794"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Korea Ministry of Science and ICT","doi-asserted-by":"publisher","award":["RS-2023-00279744"],"award-info":[{"award-number":["RS-2023-00279744"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jconrel.2024.12.039","type":"journal-article","created":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T14:23:14Z","timestamp":1735222994000},"page":"637-655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["An oral liraglutide nanomicelle formulation conferring reduced insulin-resistance and long-term hypoglycemic and lipid metabolic benefits"],"prefix":"10.1016","volume":"378","author":[{"given":"Laxman","family":"Subedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun Dhwoj","family":"Bamjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susmita","family":"Phuyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Hyun","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Sik","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Bae","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwan-Young","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngro","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seho","family":"Kweon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Woo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2024.12.039_bb0005","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2024.12.039_bb0010","first-page":"525","article-title":"The burden and risks of emerging complications of diabetes mellitus, nature reviews","volume":"18","author":"Tomic","year":"2022","journal-title":"Endocrinology"},{"key":"10.1016\/j.jconrel.2024.12.039_bb0015","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2024.12.039_bb0020","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.yexcr.2011.01.010","article-title":"GLP-1 for type 2 diabetes","volume":"317","author":"Ahr\u00e9n","year":"2011","journal-title":"Exp. Cell Res."},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2024.12.039_bb0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000433437","article-title":"Molecular pharmacology of the incretin receptors","volume":"25","author":"Al-Sabah","year":"2016","journal-title":"Med. Princ. Pract."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101762","article-title":"Discovery of ecnoglutide: a novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog","volume":"75","author":"Guo","year":"2023","journal-title":"Mol Metab"},{"key":"10.1016\/j.jconrel.2024.12.039_bb0035","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"NEJM"},{"key":"10.1016\/j.jconrel.2024.12.039_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101533","article-title":"Next generation GLP-1\/GIP\/glucagon triple agonists normalize body weight in obese mice","volume":"63","author":"Knerr","year":"2022","journal-title":"Mol Metab"},{"key":"10.1016\/j.jconrel.2024.12.039_bb0045","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.cmet.2022.07.013","article-title":"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept","volume":"34","author":"Coskun","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116471","article-title":"Peptide GLP-1 receptor agonists: from injection to oral delivery strategies","volume":"229","author":"Ke","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0055","doi-asserted-by":"crossref","first-page":"eaar7047","DOI":"10.1126\/scitranslmed.aar7047","article-title":"Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist","volume":"10","author":"Buckley","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0060","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.apsb.2021.04.001","article-title":"Oral delivery of proteins and peptides: challenges, status quo and future perspectives","volume":"11","author":"Zhu","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2024.12.039_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114097","article-title":"Oral delivery of therapeutic peptides and proteins: technology landscape of lipid-based nanocarriers","volume":"182","author":"Haddadzadegan","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0070","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s40005-022-00609-4","article-title":"Peptide permeation enhancers for improving oral bioavailability of macromolecules","volume":"53","author":"Kim","year":"2023","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0075","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s40005-023-00656-5","article-title":"Recent approaches to investigate drug delivery systems through the lymphatic pathway using oral lipid-based formulations","volume":"54","author":"Jeong","year":"2024","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0080","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12951-022-01743-9","article-title":"Intestinal epithelium penetration of liraglutide via cholic acid pre-complexation and zein\/rhamnolipids nanocomposite delivery","volume":"21","author":"Bao","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0085","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jconrel.2023.07.044","article-title":"Stimuli-responsive self-assembled polymer nanoparticles for the oral delivery of antibodies","volume":"361","author":"Miller","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.12.039_bb0090","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40005-022-00600-z","article-title":"A mechanism-based understanding of altered drug pharmacokinetics by gut microbiota","volume":"53","author":"Gulnaz","year":"2023","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0095","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jconrel.2024.04.026","article-title":"Enhanced oral and pulmonary delivery of biomacromolecules via amplified transporter targeting","volume":"370","author":"Xiao","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.12.039_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40005-023-00643-w","article-title":"Enhanced oral bioavailability of megestrol acetate via polymer-hybridized solid lipid nanoparticles using ultrasonic nebulization method","author":"Yoo","year":"2024","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0105","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jconrel.2024.01.015","article-title":"Nanoparticles targeting the intestinal fc receptor enhance intestinal cellular trafficking of semaglutide","volume":"366","author":"Pinto","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.12.039_bb0110","doi-asserted-by":"crossref","first-page":"15430","DOI":"10.1021\/acsami.5b03555","article-title":"N-trimethyl chitosan chloride-coated PLGA nanoparticles overcoming multiple barriers to oral insulin absorption","volume":"7","author":"Sheng","year":"2015","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2024.12.039_bb0115","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.ijbiomac.2018.08.078","article-title":"Development of chitosan coated calcium-alginate nanocapsules for oral delivery of liraglutide to diabetic patients","volume":"120","author":"Shamekhi","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0120","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ejps.2017.12.014","article-title":"The effect of 2-hydroxypropyl-\u03b2-cyclodextrin on the intestinal permeation through mucus","volume":"114","author":"Stappaerts","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0125","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s11154-022-09735-8","article-title":"A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes","volume":"23","author":"Aroda","year":"2022","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0130","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.biomaterials.2017.09.022","article-title":"Bile acid transporter mediated endocytosis of oral bile acid conjugated nanocomplex","volume":"147","author":"Park","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2024.12.039_bb0135","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40824-023-00421-7","article-title":"Design of chimeric GLP-1A using oligomeric bile acids to utilize transporter-mediated endocytosis for oral delivery","volume":"27","author":"Kweon","year":"2023","journal-title":"Biomater. Res."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0140","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.2147\/IJN.S442617","article-title":"Coordinated ASBT and EGFR mechanisms for optimized liraglutide nanoformulation absorption in the GI tract","volume":"19","author":"Kweon","year":"2024","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2024.12.039_bb0145","doi-asserted-by":"crossref","first-page":"7421","DOI":"10.1073\/pnas.1323599111","article-title":"Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut","volume":"111","author":"Joyce","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0150","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41392-024-01811-6","article-title":"Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets","volume":"9","author":"Fleishman","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108050","article-title":"Progression of insulin resistance: a link between risk factors and the incidence of diabetes","volume":"161","author":"Wu","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0160","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s40618-018-0836-x","article-title":"Liraglutide ameliorates palmitate-induced insulin resistance through inhibiting the IRS-1 serine phosphorylation in mouse skeletal muscle cells","volume":"41","author":"Li","year":"2018","journal-title":"J. Endocrinol. Invest."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0165","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00125-013-3145-0","article-title":"Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus","volume":"57","author":"Hogan","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.jconrel.2024.12.039_bb0170","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1210\/en.2011-1070","article-title":"Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance","volume":"152","author":"Vendrell","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.jconrel.2024.12.039_bb0175","doi-asserted-by":"crossref","first-page":"354","DOI":"10.4093\/dmj.2023.0277","article-title":"Glucagon-like peptide-1: new regulator in lipid metabolism","volume":"48","author":"Bu","year":"2024","journal-title":"Diabetes Metab. J."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0180","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1136\/gutjnl-2019-319146","article-title":"Novel strategy for oral peptide delivery in incretin-based diabetes treatment","volume":"69","author":"Xu","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2024.12.039_bb0185","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jconrel.2023.03.012","article-title":"Exploiting the biological effect exerted by lipid nanocapsules in non-alcoholic fatty liver disease","volume":"356","author":"Domingues","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.12.039_bb0190","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/osp4.84","article-title":"Liraglutide for weight management: a critical review of the evidence","volume":"3","author":"Mehta","year":"2017","journal-title":"Obes. Sci. Pract."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0195","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"NEJM"},{"key":"10.1016\/j.jconrel.2024.12.039_bb0200","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jconrel.2022.07.012","article-title":"Enhanced oral absorption of teriparatide with therapeutic potential for management of osteoporosis","volume":"349","author":"Subedi","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.12.039_bb0205","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1038\/nprot.2007.303","article-title":"Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers","volume":"2","author":"Hubatsch","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102581","article-title":"Challenges in the diagnosis of insulin resistance: focusing on the role of HOMA-IR and Tryglyceride\/glucose index","volume":"16","author":"Tahapary","year":"2022","journal-title":"Diabetes Metab. Syndr."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0215","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1194\/jlr.D023788","article-title":"Adiposoft: automated software for the analysis of white adipose tissue cellularity in histological sections","volume":"53","author":"Galarraga","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0220","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/j.1749-6632.2010.05875.x","article-title":"Adipokines as novel biomarkers and regulators of the metabolic syndrome","volume":"1212","author":"Deng","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0225","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1039\/C9NA00308H","article-title":"Hydrophobic ion pairing: encapsulating small molecules, peptides, and proteins into nanocarriers","volume":"1","author":"Ristroph","year":"2019","journal-title":"Nanoscale Adv."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0230","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejpb.2014.02.013","article-title":"Surfactants, not size or zeta-potential influence blood-brain barrier passage of polymeric nanoparticles","volume":"87","author":"Voigt","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.surfrep.2017.02.001","article-title":"Nanoparticle decoration with surfactants: molecular interactions, assembly, and applications","volume":"72","author":"Heinz","year":"2017","journal-title":"Surf. Sci. Rep."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0257824","article-title":"Caco-2\/HT29-MTX co-cultured cells as a model for studying physiological properties and toxin-induced effects on intestinal cells","volume":"16","author":"Hoffmann","year":"2021","journal-title":"PloS One"},{"key":"10.1016\/j.jconrel.2024.12.039_bb0245","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1021\/jp109545v","article-title":"Molecular simulations of dodecyl-beta-maltoside micelles in water: influence of the headgroup conformation and force field parameters","volume":"115","author":"Abel","year":"2011","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.jconrel.2024.12.039_bb0250","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.addr.2019.04.008","article-title":"Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine","volume":"143","author":"Donahue","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0255","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1073\/pnas.0712328105","article-title":"The organic solute transporter \u03b1-\u03b2, Ost\u03b1-Ost\u03b2, is essential for intestinal bile acid transport and homeostasis","volume":"105","author":"Rao","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0260","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3109\/00365521.2014.898326","article-title":"Surface area of the digestive tract\u2013revisited","volume":"49","author":"Helander","year":"2014","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0265","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J Basic Clin Pharm"},{"key":"10.1016\/j.jconrel.2024.12.039_bb0270","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/DDDT.S10180","article-title":"Liraglutide in the management of type 2 diabetes","volume":"4","author":"Wajcberg","year":"2010","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0275","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s40262-021-01025-x","article-title":"Clinical pharmacokinetics of oral semaglutide: analyses of data from clinical pharmacology trials","volume":"60","author":"Overgaard","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0280","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ijo.2011.158","article-title":"Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide","volume":"36","author":"Astrup","year":"2012","journal-title":"Int. J. Obes. (Lond)"},{"key":"10.1016\/j.jconrel.2024.12.039_bb0285","doi-asserted-by":"crossref","first-page":"778","DOI":"10.2337\/db12-0073","article-title":"Insulin resistance and type 2 diabetes","volume":"61","author":"Taylor","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.jconrel.2024.12.039_bb0290","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1007\/s00125-021-05415-5","article-title":"Defining the underlying defect in insulin action in type 2 diabetes","volume":"64","author":"Batista","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.jconrel.2024.12.039_bb0295","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/s12276-023-01043-8","article-title":"Reversing pancreatic \u03b2-cell dedifferentiation in the treatment of type 2 diabetes","volume":"55","author":"Son","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0300","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2337\/diabetes.52.1.124","article-title":"Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor","volume":"52","author":"Buteau","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.jconrel.2024.12.039_bb0305","article-title":"Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass","volume":"2011","author":"Portha","year":"2011","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0310","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101090","article-title":"Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease","volume":"46","author":"Baggio","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.jconrel.2024.12.039_bb0320","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.2337\/db14-0302","article-title":"GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK","volume":"63","author":"Beiroa","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.jconrel.2024.12.039_bb0325","doi-asserted-by":"crossref","first-page":"18522","DOI":"10.1038\/s41598-021-97967-0","article-title":"Effect of liraglutide on expression of inflammatory genes in type 2 diabetes","volume":"11","author":"Zobel","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2024.12.039_bb0330","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924008915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924008915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T12:45:28Z","timestamp":1778244328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924008915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":66,"alternative-id":["S0168365924008915"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.12.039","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An oral liraglutide nanomicelle formulation conferring reduced insulin-resistance and long-term hypoglycemic and lipid metabolic benefits","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.12.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}